Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Vaccine for Female Participants Only Clear all
Terminated Phase 1Phase 2 Interventional Results available

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

NCT03610581
View directory record Official record
Conditions
Human Papillomavirus Infections
Interventions
Ad26.HPV16, Ad26.HPV18, MVA.HPV16/18, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Doral, Florida • Fort Myers, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 6, 2026, 1:09 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

NCT04605159
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11,194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 6, 2026, 1:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Months to 79 Years
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
31
States / cities
La Mesa, California • West Hollywood, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 6, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

NCT05045144
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,586 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 6, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women

NCT01461096
View directory record Official record
Conditions
HIV Infections
Interventions
Quadrivalent HPV Vaccine, Placebo Vaccine for Male Participants Only, Placebo Vaccine for Female Participants Only
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
27 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 6, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

NCT06143046
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
mRNA-1345, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
0 Years to 40 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 6, 2026, 1:09 AM EDT